IRIX
$1.34+0.01 (+0.75%)
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.
Recent News
Zacks Initiates Coverage of Iridex With Neutral Recommendation
Discover why Zacks initiated coverage of IRIX with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how global sales momentum and stronger liquidity are balanced against margin pressures and dependency on a key distributor.
IRIDEX Corp (IRIX) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic Cost Management
IRIDEX Corp (IRIX) reports its fourth consecutive quarter of revenue growth, driven by strong glaucoma product sales and strategic cost-saving measures.
Iridex: Q3 Earnings Snapshot
MOUNTAIN VIEW, Calif. AP) — Iridex Corp. IRIX) on Tuesday reported a loss of $1.6 million in its third quarter.
IRIDEX Corp (IRIX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Cost Challenges
IRIDEX Corp (IRIX) reports a 7% year-over-year revenue increase and continues its cost reduction strategy, despite facing margin pressures and international market challenges.
Iridex: Q2 Earnings Snapshot
MOUNTAIN VIEW, Calif. AP) — Iridex Corp. IRIX) on Tuesday reported a loss of $994,000 in its second quarter.